Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 18;26(10):4822.
doi: 10.3390/ijms26104822.

Opposing Calcium-Dependent Effects of GsMTx4 in Acute Lymphoblastic Leukemia: In Vitro Proliferation vs. In Vivo Survival Advantage

Affiliations

Opposing Calcium-Dependent Effects of GsMTx4 in Acute Lymphoblastic Leukemia: In Vitro Proliferation vs. In Vivo Survival Advantage

Souleymane Abdoul-Azize et al. Int J Mol Sci. .

Abstract

Mechanogated (MG) ion channels play a crucial role in mechano-transduction and immune cell regulation, yet their impact on blood cancers, particularly acute lymphoblastic leukemia (ALL), remains poorly understood. This study investigates the pharmacological effects of GsMTx4, an MG channel inhibitor, in human ALL cells both in vitro and in vivo. Unexpectedly, we found that GsMTx4 remarkably increased basal calcium (Ca2+) levels in ALL cells through constitutive Ca2+ entry and enhanced store-operated Ca2⁺ influx upon thapsigargin stimulation. This increase in basal Ca2+ signaling promoted ALL cell viability and proliferation in vitro. Notably, chelating intracellular Ca2+ with BAPTA-AM reduces GsMTx4-mediated leukemia cell viability and proliferation. However, in vivo, GsMTx4 decreases cytosolic Ca2+ levels in Nalm-6 GFP⁺ cells isolated from mouse blood, effectively countering leukemia progression and significantly extending survival in NSG mice transplanted with leukemia cells (median survival: GsMTx4 vs. control, 37.5 days vs. 29 days, p = 0.0414). Our results highlight the different properties of GsMTx4 activity in in vitro and in vivo models. They also emphasize that Ca2+ signaling is a key vulnerability in leukemia, where its precise modulation dictates disease progression. Thus, targeting Ca2+ channels could offer a novel therapeutic strategy for leukemia by exploiting Ca2+ homeostasis.

Keywords: ALL; Ca2+ signaling; GsMTx4; cell survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Mechanogated ion channel inhibitor (GsMTx4) enhances basal Ca2+ levels in ALL cell lines. The basal Ca2+ level was used as a read-out to measure the impact of GsMTX4 on constitutive Ca2+ channel activity in ALL cells. (AE) ALL cell lines pre-treated with control (Ctr, DMSO) and GsMTx4 using the ratiometric Ca2+ indicator Fura-2 QBT. The basal Ca2+ level was evaluated before normalization as the average of initial F340 nm/F380 nm values. Data are mean ± SEM (n = 3). Statistical significance was analyzed by two-tailed, unpaired Student’s t-tests.
Figure 2
Figure 2
GsMTx4 increases Mn2+ influx in ALL cell lines. The quenching of Fura-2 fluorescence by Mn2+ in ALL cell lines was measured at 360 nm (the Ca2+-independent excitation wavelength of Fura-2). (AE) ALL cells before exposure to Mn2+ (10 μM) were preincubated during Fura-2 GBT loading with GsMTx4. Results express normalized fluorescence and quenching peak quantification. Data are mean ± SEM (n = 5). Statistical significance was analyzed by two-tailed, unpaired Student’s t-tests. * p < 0.05, *** p < 0.001, and **** p < 0.0001.
Figure 3
Figure 3
GsMTx4 potentiates store-operated Ca2+ entry (SOCE) in ALL cell lines. (AC) Representative traces and quantification of SOCE peak upon store depletion in 0 mM Ca2+ with 2 µM TG (thapsigargin) followed by addition of 1.8 mM Ca2+ to the solution. Cells before exposure to TG in Ca2+ buffer were preincubated during Fura-2 QBT loading with GsMTx4. Data are mean ± SEM (n = 4). Statistical significance was analyzed by two-tailed, unpaired Student’s t-tests.
Figure 4
Figure 4
GsMTx4 stimulates proliferation and viability of ALL cells through Ca2+ signaling. (A) ALL cell lines were treated with GsMTx4 for 48 h. Then, the proliferation rate was determined by CCk-8 staining. The percentage was established after normalizing on control (Ctr) cells. (B,C) ALL cell lines were treated with GsMTx4 for 48 h in the absence or presence of BAPTA-AM (1 μM). (B) Cell proliferation rate was determined by CCK-8 assay. (C) Cell viability was determined by flow cytometry after annexin V/PI staining. Viable cells represent the percentage of annexin V-FITC/PI- negative population. Data are mean ± SEM (n = 3). Statistical significance was analyzed by two-tailed, unpaired Student’s t-tests; ns, not significant.
Figure 5
Figure 5
GsMTx4 decreases cytosolic Ca2+ levels of ALL cells and prolongs overall survival of NSG mice in vivo. (A) Experimental design of NSG mice treatment experiments. BLI, bioluminescence imaging. (B) Flow cytometry Ca2+ assessment in Nalm-6 GFP+ cells in the blood at day 16. (C) An example of bioluminescence imaging of Nalm-6 GFP/luc at days 14 and 28 of tumor challenge. (D) Kaplan–Meier survival analysis of mice transplanted with Nalm-6 GFP-luc cells and treated with Ctr (DMSO, n = 4) and GsMTx4 (n = 4). Statistical significance was calculated with the log-rank (Mantel–Cox) test, (* p = 0.041).

Similar articles

References

    1. Conter V., Aricò M., Basso G., Biondi A., Barisone E., Messina C., Parasole R., De Rossi G., Locatelli F., Pession A., et al. EDUCATIONAL REPORT Long-Term Results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for Childhood Acute Lymphoblastic Leukemia. Leukemia. 2010;24:255–264. doi: 10.1038/leu.2009.250. - DOI - PubMed
    1. Hefazi M., Litzow M.R. Recent Advances in the Biology and Treatment of B-Cell Acute Lymphoblastic Leukemia. Blood Lymphat. Cancer Targets Ther. 2018;8:47–61. doi: 10.2147/BLCTT.S170351. - DOI - PMC - PubMed
    1. Serafin V., Capuzzo G., Milani G., Minuzzo S.A., Pinazza M., Bortolozzi R., Bresolin S., Porcù E., Frasson C., Indraccolo S., et al. Glucocorticoid Resistance Is Reverted by LCK Inhibition in Pediatric T-Cell Acute Lymphoblastic Leukemia. Blood. 2017;130:2750–2761. doi: 10.1182/blood-2017-05-784603. - DOI - PubMed
    1. Graff Z., Burke M.J., Gossai N. Novel Therapies for Pediatric Acute Lymphoblastic Leukemia. Curr. Opin. Pediatr. 2024;36:64–70. doi: 10.1097/MOP.0000000000001316. - DOI - PubMed
    1. Oskarsson T., Söderhäll S., Arvidson J., Forestier E., Frandsen T.L., Hellebostad M., Lähteenmäki P., Jónsson Ó.G., Myrberg I.H., Heyman M., et al. Treatment-Related Mortality in Relapsed Childhood Acute Lymphoblastic Leukemia. Pediatr. Blood Cancer. 2018;65:e26909. doi: 10.1002/pbc.26909. - DOI - PubMed

MeSH terms

LinkOut - more resources